Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (819)	6/1/2004 7:35:31 PM
From: A.J. Mullen	Respond to of 2240

I see Dana Farber is recruiting lung cancer (NSLC) patients for small Phase 1 pilot trial of MDX-010 against a variety of cancers. clinicaltrials.gov Ashley

To: A.J. Mullen who wrote (819)	6/2/2004 1:34:05 AM
From: Icebrg	Read Replies (2) \| Respond to of 2240

Ashley I believe that there were a couple of commercial considerations that made metastatic melanoma a suitable target. 1. There are no approved effective treatments for second-line metastatic melanoma today. That should mean that the road to approval (if efficacy can be proved) should be relatively easy. 2. Medarex needs a cancer vaccine to work in combination with MDX-010. I suspect that they very much preferred to start with to work with a vaccine where no other companies were involved. Erik